In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including:

Current systemic therapy standards of care for patients with advanced HCC
Use of single-agent immune checkpoint inhibitor therapy in the first-line setting
Assessing bleeding risk
Using immunotherapy in patients with active HBV or HCV infections

Presenters:

David Kaplan, MD, MSc
Associate Professor
Perelman School of Medicine
University of Pennsylvania
Director of Hepatology
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Thomas Karasic, MD
Assistant Professor of Medicine
Department of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.

Link to full program:
https://bit.ly/39V6s72

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions